By Fineline Cube 
Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding round totaling RMB 100 million (USD 14 million). The round was led by Panlin Capital, with participation from Hangzhou Shangcheng District State Owned Capital Operation Group, KingHall Ventures, and Hangzhou Science and Technology Innovation Group. WinX Capital served as the exclusive financial advisor.
Funding and Objectives
The proceeds from this funding round will be utilized to accelerate the clinical registration of Dessight Biomedical’s universal microsurgical robot and to advance the commercialization of its ophthalmic surgical robot. This investment aims to reinforce the company’s technological leadership and expand its portfolio of robotic microsurgical systems.
Company Background
Established in July 2021, Dessight Biomedical is recognized as a national high-tech enterprise and a “Specialized, Refined, Unique, and Innovative” SME in Zhejiang Province. The company is also a co-builder of a key provincial laboratory and holds a leading position in the research and development and commercialization of microsurgical robotics.
Innovation and Achievements
To date, Dessight Biomedical has filed and obtained dozens of invention patents in both China and the United States. Its ophthalmic surgical robot has completed China’s first registration clinical trials in several top-tier hospitals. The product has also entered the “green channel” of the National Medical Products Administration (NMPA) for the special review of innovative medical devices, highlighting its innovative capabilities and technological advantages.-Fineline Info & Tech